FDA approves neratinib to limit breast cancer recurrence risk

The U.S. Food and Drug Administration has approved neratinib for the extended adjuvant treatment of early-stage, HER2-positive breast cancer. For patients with this type of cancer, neratinib is the first extended adjuvant therapy, a form of therapy that...

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2tlNQJm
via IFTTT